Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy
| Autor: | Nissar A. Wani, Parvaiz Yousuf, Ajaz A. Bhat, Surinder K. Batra, Shyam S. Chauhan, Mohammad Haris, Davide Bedognetti, Mushtaq A. Siddiqi, Muzafar A. Macha, Arshi Rizwan, Wael El-Rifai, Michael P. Frenneaux |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer microenvironment Cancer Research Angiogenesis medicine.medical_treatment lcsh:Medicine Review Article medicine.disease_cause Targeted therapy 03 medical and health sciences 0302 clinical medicine Immune system Chemoimmunotherapy Tumor Microenvironment Genetics medicine Humans Head and neck cancer lcsh:QH301-705.5 Tumor microenvironment Squamous Cell Carcinoma of Head and Neck business.industry lcsh:R Correction medicine.disease Head and neck squamous-cell carcinoma stomatognathic diseases 030104 developmental biology lcsh:Biology (General) Head and Neck Neoplasms 030220 oncology & carcinogenesis Cancer research business Carcinogenesis |
| Zdroj: | Signal Transduction and Targeted Therapy, Vol 6, Iss 1, Pp 1-15 (2021) Signal Transduction and Targeted Therapy |
| ISSN: | 2059-3635 |
| Popis: | Head and neck squamous cell carcinoma (HNSCC) is a very aggressive disease with a poor prognosis for advanced-stage tumors. Recent clinical, genomic, and cellular studies have revealed the highly heterogeneous and immunosuppressive nature of HNSCC. Despite significant advances in multimodal therapeutic interventions, failure to cure and recurrence are common and account for most deaths. It is becoming increasingly apparent that tumor microenvironment (TME) plays a critical role in HNSCC tumorigenesis, promotes the evolution of aggressive tumors and resistance to therapy, and thereby adversely affects the prognosis. A complete understanding of the TME factors, together with the highly complex tumor–stromal interactions, can lead to new therapeutic interventions in HNSCC. Interestingly, different molecular and immune landscapes between HPV+ve and HPV−ve (human papillomavirus) HNSCC tumors offer new opportunities for developing individualized, targeted chemoimmunotherapy (CIT) regimen. This review highlights the current understanding of the complexity between HPV+ve and HPV−ve HNSCC TME and various tumor–stromal cross-talk modulating processes, including epithelial–mesenchymal transition (EMT), anoikis resistance, angiogenesis, immune surveillance, metastatic niche, therapeutic resistance, and development of an aggressive tumor phenotype. Furthermore, we summarize the recent developments and the rationale behind CIT strategies and their clinical applications in HPV+ve and HPV−ve HNSCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|